ArticleFrontiers in oncology2023

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial.

Dingyuan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.